Clinical trial · Observational
Metabolic Changes as a Diagnostic Indicator for Cancer
NCT02362776CI-TRIAL-00016865completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to determine whether metabolic changes occur in blood plasma of cancer patients, and whether these changes can be used as a biomarker to detect cancer. These analyses will be done by means of nuclear magnetic resonance (NMR) spectroscopy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Venous blood sample | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- breast cancer patients
- interventionNames
- Other: Venous blood sample
- label
- lung cancer patients
- interventionNames
- Other: Venous blood sample
- label
- control subjects
- interventionNames
- Other: Venous blood sample
Primary outcomes (1)
- measure
- Metabolic phenotype of cancer
- timeFrame
- day 1
- description
- Significant metabolic changes in blood between cancer patients \& control subjects
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of breast or lung cancer (new lesion) Exclusion Criteria: * Not fasted for at least 6 hours * Plasma glucose concentration ≥ 200 mg/dl * Intake of medication at the day of investigation * History/treatment of cancer in the previous 5 years
References
Publications (1)
- DERIVEDLouis E, Adriaensens P, Guedens W, Vanhove K, Vandeurzen K, Darquennes K, Vansteenkiste J, Dooms C, de Jonge E, Thomeer M, Mesotten L. Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types? Ann Oncol. 2016 Jan;27(1):178-84. doi: 10.1093/annonc/mdv499. Epub 2015 Oct 20. PMID 26487580